linjc16/ctgov huggingface dataset:
Role of Sphingolipids in Pulmonary Edema

Study Overview
=================
Brief Summary
-----------------
In this mono-center prospective study, the impact of changes in the sphingolipid metabolism in patients with pulmonary edema will be investigated.

Detailed Description
-----------------
There will be three groups of patients: hydrostatic pulmonary edema toxic pulmonary edema not ventilated patients without any pulmonary edema Samples of a routine bronchoalveolar lavage and EDTA-blood will be analysed in respect of sphingolipids, ceramide, sphingomyelin-phosphodiesterase and several cytokines.

Official Title
-----------------
Role of Sphingolipids in Pulmonary Edema

Conditions
-----------------
Pulmonary Edema

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above the age of 18 Exclusion Criteria: taking steroids

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hydrostatic pulmonary edema<br>patients with a pulmonary edema caused by chronic heart failure | |
| toxic pulmonary edema<br>patients with a pulmonary edema preceded by pneumonia | |
| control group<br>not ventilated patients without any pulmonary edema receiving a bronchoscopy due to another pulmonary problem (no pneumonia, no heart failure) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sphingolipid, ceramide, sphingomyelinase
Biological Markers Predicting Exercise Capacity in CF-LVAD Patients.

Study Overview
=================
Brief Summary
-----------------
Establishing the association between biological markers and exercise capacity in continuous-flow left ventricular assist device patients.

Detailed Description
-----------------
The aim of this study is to investigate if specific biological markers can predict exercise capacity in advanced heart failure patients supported with continuous-flow left ventricular assist device patients.

Official Title
-----------------
Biological Markers Predicting Exercise Capacity in Heart Failure Patients Supported With a Continuous-flow Left Ventricular Assist Device.

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Stable CF-LVAD patients. Exclusion Criteria: Unstable CF-LVAD patients.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Biological markers | Analysis of blood will be carried out on all samples simultaneously, expected markers are pro-BNP, MRproANP, copeptin, Gal-3 and proADM. | Blood sampling on study day and samples are subsequently stored frozen. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exercise capacity | Exercise capacity will be estimated by peak VO2 measurements on a upright ergometer bike with breath-by-breath gas analysis. | Examination on study day. Patients will only be followed on the day of the study. Exercise testing is performed as the last intervention on the study day. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Exercise
Acceptability Study by Patients Admitted for Suicide and by Medical Staff for Clinical Data Collection Through an E-health Platform

Study Overview
=================
Brief Summary
-----------------
The study goal is to determine the feasbility and interest of monitoring mental health and non mental health related simptoms in Outpatients in order to prevent suicide.

Detailed Description
-----------------
Taking into account the strengths and pitfalls of existing suicide risk assessment methods, we have designed a system capable to combine EMA and continuous monitoring of patients using the smartphone's and/or wearable's sensors and data entry in order to monitor and predict suicide risk. For example, both poor sleep quality and disturbed appetite are clinical markers of depression, with a bidirectional relationship. Their changes could precede the increase of suicidal behavior as sleep and appetite are both influenced by mood state and regulated by the serotonergic system. Our hypothesis is that tracking mental health simptoms regularly through self-report could serve as a consistent and non-biased shortcut to assess mood state, its biological underpinnings and could potentially predict suicidal behavior.

Official Title
-----------------
Acceptability Study SMARTphone to Collect Clinical Data Using the Memind App by Patients and Medical Satff.

Conditions
-----------------
Suicide, Attempted

Participation Criteria
=================
Eligibility Criteria
-----------------
To be eligible for the study, patients must be 18 years or older, attend an outpatient clinic or emergency departments of participating clinical services and owning an android or IOS smartphone

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the feasibility of this intensive data capture technology in patients in real world without economical incentives. | acceptability assessed by the AES scale | 2 month |
Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells

Study Overview
=================
Brief Summary
-----------------
The study is to investigate the efficacy and safety of allogenous transplantation of adipose-derived mesenchyma stem cells in patients with cerebellar ataxia.

Official Title
-----------------
Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells

Conditions
-----------------
Cerebellar Ataxia

Intervention / Treatment
-----------------
* Biological: Allogeneic adult adipose-derived mesenchymal stem cells


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients diagnosed of spinocerebellar ataxia 3 (SCA3) or multiple system atrophy-cerebellar (MSA-C). Subject's SARA score at 10 20 points. Ages between 20 70 years. Signed informed consent from the patient and/or guardian. Exclusion Criteria: Subjects enrolled in any other cell therapy studies within the past 30 days. Pregnancy test positive. Subjects deemed to be not suitable for the study by the investigator.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mesenchymal stem cells(MSC) treatment<br>All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells | Biological: Allogeneic adult adipose-derived mesenchymal stem cells<br>* Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety evaluation | Safety evaluate through vital signs, the results of clinical lab tests and adverse events (AEs) | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alterations in SARA score |  | 12 months | 
| Positron emission tomography | 18F-FDG used for the assessment of glucose metabolism in the brain | 9 months | 
| Magnetic resonance spectroscopy | NAA/Cr,Cho/Cr,NAA/Cho ratios to reflect neuronal/cerebral white mater integrity | 12 months | 
| Assessment of language and swallowing functions | changes in levels of severity: normal/slight/mild/moderate/severe | 12 months | 
| Evaluation of syncope | Tilt table test | 12 months | 
| Balance test |  | 12 months |
Comparison of Buprenorphine and Methadone - 3

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare agonist and antagonist profile associated with buprenorphine vs. methadone during opiate withdrawal.

Official Title
-----------------
Pharmacological Comparison of Buprenorphine and Methadone

Conditions
-----------------
Opioid-Related Disorders

Intervention / Treatment
-----------------
* Drug: Buprenorphine


Participation Criteria
=================
Eligibility Criteria
-----------------
Please contact site for information.

Ages Eligible for Study
-----------------
Minimum Age: 23 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Buprenorphine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Withdrawal severity |  |  | 
| Opiate agonist symptoms |  |  |
Application of Vascular Closure Device in Transvenous Cardiac Intervention

Study Overview
=================
Brief Summary
-----------------
Comparison of safety and efficacy between the application of vascular closure device and conventional figure-of-eight suture in transvenous cardiac interventional surgery

Detailed Description
-----------------
Comparison of safety and efficacy between the application of vascular closure device and conventional figure-of-eight suture in transvenous cardiac interventional surgery.From the operation success rate, postoperative bleeding, immobilization time, the rate of revisiting the doctor due to wound problems within 1 month, etc.

Official Title
-----------------
Comparison of Safety and Efficacy Between the Application of Vascular Closure Device and Conventional Figure-of-eight Suture in Transvenous Cardiac Interventional Surgery

Conditions
-----------------
Vascular Access Complications

Intervention / Treatment
-----------------
* Procedure: Vascular closure device
* Procedure: figure eight stitch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients receiving lower extremity venous intervention with a diameter of 12F or more Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Proglide group<br>Vascular Sutures for Transvenous Cardiac Interventions Using Proglide | Procedure: Vascular closure device<br>* Suture of lower extremity veins using the Proglide Vascular Closure Device<br>|
| Active Comparator: figure eight stitch<br>Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures | Procedure: figure eight stitch<br>* Vascular Sutures for Transvenous Cardiac Intervention Using Conventional Figure-8 Sutures<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Vascular bleeding event rate | Proportion of bleeding after two methods of vascular suturing | 1month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bed braking time | Postoperative bed rest time | 1 day |
Assessment of Video Assisted Thoracoscopic Surgery (VATS) Versus Open Surgery for Patients Undergoing Lobectomy

Study Overview
=================
Brief Summary
-----------------
Assessment of VATS versus standard open surgery for treatment of non small cell lung cancer.

Official Title
-----------------
A Prospective, Single Center, Observational Study Comparing the Safety and Efficacy of CVATS, HVATS and Open Surgery for Subjects Diagnosed With NSCLC Scheduled to Undergo a Lobectomy

Conditions
-----------------
Non Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Procedure: Lobectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject must be 18 years of age or older. Subject must have been clinically diagnosed with stage I to stage IIA non small cell lung cancer measuring and judged to be resectable. Subject must be able to tolerate general anesthesia, and have cardiopulmonary reserve to tolerate a lobectomy Exclusion Criteria: Subject is pregnant (documented by pregnancy test) or breastfeeding. Subject has other severe illnesses that would preclude surgery such as Unstable angina Myocardial Infarction within 3 months Coronary Artery Bypass Graft Surgery Subject has other active cancers Subject is unable to comply with any of the following: Study requirements Give valid informed consent Follow-up schedule

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group A<br>VATS | Procedure: Lobectomy<br>* Assessment of VATS versus open surgery.<br>* Other names: HVATS;|
| Group B<br>Open Surgery | Procedure: Lobectomy<br>* Assessment of VATS versus open surgery.<br>* Other names: HVATS;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess hospital length of stay (LOS). |  | 1 time point (discharge) | 
| Pain Scale Evaluation |  | 5 time points out to 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assess quality of life. |  | 2 time points out to 6 months | 
| Assess peri-operative and post-operative complications. |  | 5 time points out to 6 months. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
VATS, Lung cancer, NSCLC
Study Evaluating the Efficacy and Safety of Cyclosporine Reduction in Kidney Transplant Recipients Receiving Sirolimus

Study Overview
=================
Brief Summary
-----------------
To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients.

Detailed Description
-----------------
To evaluate the safety and efficacy of different doses of cyclosporine given concomitantly with a fixed dose of sirolimus in kidney transplant recipients. Cyclosporine blood levels, graft rejection rates and renal function will be assessed.

Official Title
-----------------
An Open-Label Study to Evaluate the Efficacy and Safety of Cyclosporine Reduction in de Novo Renal Allograft Recipients Receiving Sirolimus: a Dose Comparative Study

Conditions
-----------------
Kidney Transplantation

Intervention / Treatment
-----------------
* Drug: Sirolimus
* Drug: Cyclosporine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria At least 18 years of age End-stage renal disease in patients receiving a primary or secondary renal allograft from a cadaveric, living-unrelated, or living-related mismatched donor Patients with secondary kidney transplant must have maintained primary graft for at least 6 months Exclusion criteria Antibody induction within one week of current transplantation Multiorgan transplants Patients at high-risk of rejection

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Sirolimus|nan|
|Drug: Cyclosporine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A dose response model using the average cyclosporine blood levels correlated to graft rejection rates and renal function will be used to compare efficacy and safety of different doses of cyclosporine. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety evaluations will include physical exams, vital signs, CBC with differential, platelet count, blood chemistries, fasting lipid profiles, BUN or urea, serum creatinine, adverse event monitoring and calculated creatinine clearance. |  |  |
Perspectives and Management of Atypical Asthma

Study Overview
=================
Brief Summary
-----------------
To evaluate the awareness/knowledge, clinical practice of atypical asthma among respiratory specialists and primary care practitioners (PCPs) in China.A total of 1166 respiratory specialists and 799 PCPs participated in the questionnaire survey via WeChat. The questionnaire included six major items, divided into physician demographic characteristics, awareness, diagnosis, medication prescription, assessment/education, and proposal.

Official Title
-----------------
Perspectives and Management of Atypical Asthma in Chinese Specialists and Primary Care Practitioners -- A Nationwide Questionnaire Survey.

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Other: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Grade Hospital Respiratory Doctor，Pediatrician，And doctors in primary hospitals Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Physician<br> | Other: Questionnaire<br>* physicians will participate in the questionnaire via WeChat. The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete the questionnaire | The questionnaire included six main items: physician demographic characteristics, awareness, diagnosis, medical prescription, assessment/education, and proposal. | 30 minutes |
Screening for Hemoglobinopathies in Pregnant Women

Study Overview
=================
Brief Summary
-----------------
This prospective monocentric study project is to identify hemoglobinopathies in pregnant women in order to optimize antenatal care and to investigate the prevalence of hemoglobinopathies in pregnant women in Switzerland.

Official Title
-----------------
Screening for Hemoglobinopathies in Pregnant Women

Conditions
-----------------
Hemoglobinopathies

Intervention / Treatment
-----------------
* Diagnostic Test: Review of routine lab data


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pregnant women seen at the Frauenklinik at University Hospital Basel Exclusion Criteria: pregnant women with already known hemoglobinopathy refusal of participation
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Review of routine lab data|Review of routine lab data from pregnant women (first trimester)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| identification of hemoglobinopathies | identification of hemoglobinopathies by investigating routine lab samples | single time point assessment at baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thalassemia, sickle cell anaemia, molecular genetic analysis